Trial Profile
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 May 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
- Indications Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 10 Apr 2017 Status changed from recruiting to discontinued, due to slow accrual.
- 02 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 23 Sep 2014 New trial record